Hydantoins- serum hydantoin levels and half-life may be decreased by phenacemide.

Severe epilepsy

ANTICONVULSANTS INCLUDES - BARBITURATES - OXAZOLIDINEDIONES- MISCELLANEOUS- Phenobarbitone Paramethadione Lamotrigine Trimethadione Primidone HYDANTOINS- Valproic acid Phenytoin BENZODIAPINES- Cabamazepine Mephenytoin Clonazepam Phenacemide Ethotoin Clorazepate Felbamate Diazepam Gabapentin SUCCINIMIDES- Ethosuximide Methsuximide Phensuximide REFER PHENYTOIN SODIUM -

GI disturbances, including anorexia, and weight loss. Drowsiness, headache, insomnia,dizziness, paresthesias. Abnormal urinary findings(including a rise in serum creatinine ). Psychic changes, skin rash, hepatitis.

None reported

Special precautions: Toxicity and severe side effects. Behavioural effects- caution while treating patients who have shown personality disorders. Perform complete blood counts before initiating therapy, and at monthly intervals thereafter. Renal effects. hepatic function impairment.

Indications: Severe epilepsy

Dosage:

Phenacemide may produce serious toxic effects,, therfore keep the dosage at the minimum amount necessary to acheive therapeutic effects.

Adults- Starting dose- 1.5g/day administered in 3 divided doses of 500mg each. After the first week if seizures are not controlled and the drug is well tolerated, an additional 500mg may be taken upon arising. In the third week, if necessary, the dose may be further increased by 500mg at bedtime.

Children (5 to 10 years)- give approx 1/2 the adult dose at the same intervals as for adults

ANTICONVULSANTS INCLUDES - BARBITURATES - OXAZOLIDINEDIONES- MISCELLANEOUS- Phenobarbitone Paramethadione Lamotrigine Trimethadione Primidone HYDANTOINS- Valproic acid Phenytoin BENZODIAPINES- Cabamazepine Mephenytoin Clonazepam Phenacemide Ethotoin Clorazepate Felbamate Diazepam Gabapentin SUCCINIMIDES- Ethosuximide Methsuximide Phensuximide REFER PHENYTOIN SODIUM -

Pharmacology: In animals, phenacemide in doses well below those causing neurological signs elevates the threshold for minimal elctroshock convulsions and abolishes the tonic phase of maximal electroshock seizures.

Pharmacokinetics: Phenacemide is well absorbed from the intestine and is degraded by the liver.

Pregnancy: Phenacemide can cause fetal harm if administered to pregnant woman. If phenacemide is used during pregnancy or if the patient becomes pregnant while taking the drug, appraise of the potential hazard to the fetus.

Lactation: Because of the potential for serious adverse reactions, decide whether to discontinue the drug or discontinue nursing taking into account the importance of the drug to the mother.